SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Clinical trials for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) explained in plain language.
Never miss a new study
Get alerted when new SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) trials appear
Sign up with your email to follow new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a dengue vaccine protect those with autoimmune conditions?
⭐️ VACCINE ⭐️ Recruiting nowThis study is testing a live attenuated dengue vaccine (Butantan-DV) in people aged 12–59 with autoimmune rheumatic diseases like rheumatoid arthritis or lupus, who are stable and on low or no immune-suppressing drugs. Researchers want to see if the vaccine is safe and triggers a…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE4 • Sponsor: University of Sao Paulo General Hospital • Aim: ⭐️ VACCINE ⭐️
Last updated May 26, 2026 05:29 UTC
-
Engineered immune cells take on tough lupus cases
Disease control Recruiting nowThis study tests a new treatment using a patient's own immune cells, modified to attack lupus-causing cells, for people with severe lupus that hasn't responded to standard therapies. About 18 participants aged 3 to 65 will receive the therapy and be monitored for safety and disea…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 26, 2026 05:42 UTC
-
Experimental cell therapy takes on lupus and other autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new cell therapy called YTS109 in 18 adults with hard-to-treat autoimmune diseases like lupus and Sjogren's syndrome. Participants receive a single infusion of these specially designed cells. The main goal is to see if the treatment is safe, and res…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 05:40 UTC
-
Engineered immune cells take on tough autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new treatment called CT1190B CAR-T cell therapy in 27 adults with moderate to severe lupus or systemic sclerosis that hasn't responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and calm the overactive …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated May 26, 2026 05:40 UTC
-
New lupus drug YK012 enters human trials – hope for patients with moderate to severe disease
Disease control Recruiting nowThis study tests a new drug, YK012, in about 189 adults with moderate to severe systemic lupus erythematosus (SLE). The goal is to see if it is safe and can help control the disease. Participants will receive the drug and be monitored for side effects and how well it works. This …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: Excyte Biopharma Ltd • Aim: Disease control
Last updated May 26, 2026 05:39 UTC
-
New lupus drug candidate enters human trials
Disease control Recruiting nowThis study tests a new antibody drug called SSGJ-626 in people with systemic lupus erythematosus (SLE). The goal is to see if it is safe and can help control the disease. About 198 adults aged 18 to 70 with SLE will receive either the drug or a placebo. The study is currently rec…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 05:39 UTC
-
New drug trial aims to tame autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new medicine, SAR448501/DR-0201, in adults with lupus or rheumatoid arthritis. The goal is to find safe and tolerable doses by checking side effects and how the drug works in the body. About 62 participants will receive multiple doses and be followe…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Sanofi • Aim: Disease control
Last updated May 26, 2026 05:38 UTC
-
Experimental CAR-T therapy targets lupus, ITP, and myositis in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment called BZE2204 for people with three autoimmune diseases: lupus, ITP, and inflammatory myopathies. The treatment uses the patient's own immune cells, modified to attack faulty immune cells that cause the disease. The main goals are to …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: Shanghai Cell Therapy Group Co.,Ltd • Aim: Disease control
Last updated May 26, 2026 05:38 UTC
-
New global study to see if lupus drug anifrolumab delivers Real-World relief
Disease control Recruiting nowThis study follows 200 adults with systemic lupus erythematosus (SLE) who are starting anifrolumab for the first time as part of their regular treatment. Researchers will track disease activity, skin symptoms, fatigue, and quality of life over time using standard medical assessme…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: AstraZeneca • Aim: Disease control
Last updated May 26, 2026 05:36 UTC
-
New drug hope for kids with tough-to-treat lupus
Disease control Recruiting nowThis early study tests if blinatumomab can help children with severe lupus that hasn't responded to other treatments. Six participants will receive two short courses of the drug and be monitored for a year. The goal is to see if symptoms improve and to track any side effects.
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Mao Jianhua • Aim: Disease control
Last updated May 26, 2026 05:33 UTC
-
New lupus drug cizutamig enters human testing
Disease control Recruiting nowThis early-stage study tests a new drug, cizutamig, in 47 adults with systemic lupus erythematosus (SLE) who haven't responded well to standard treatments. The main goal is to check the drug's safety and how the body processes it. Researchers will also look for signs that the dru…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Candid Therapeutics • Aim: Disease control
Last updated May 26, 2026 05:32 UTC
-
New hope for lupus patients: experimental drug PIT565 enters human trials
Disease control Recruiting nowThis early-stage study is testing a new drug called PIT565 in 54 adults with active lupus who haven't gotten better with standard treatments. The main goal is to see if the drug is safe and how the body processes it. Researchers will monitor side effects and measure drug levels i…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 05:32 UTC
-
Experimental cell therapy targets tough autoimmune cases
Disease control Recruiting nowThis early-stage study tests a new cell treatment called YTS109 in about 18 adults with autoimmune diseases like lupus or scleroderma that have not responded to standard therapies. Participants receive a single infusion of these modified immune cells. The main goal is to check sa…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 05:31 UTC
-
Revolutionary One-Shot CAR-T treatment targets lupus and more
Disease control Recruiting nowThis early-phase study tests a new therapy called TI-0032-III for people with severe autoimmune diseases like lupus that haven't responded to other treatments. The therapy uses a special injection to create cancer-fighting cells inside the body that target and destroy faulty immu…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Therorna • Aim: Disease control
Last updated May 26, 2026 05:30 UTC
-
Lupus cell therapy trial for teens shows promise
Disease control Recruiting nowThis study tests a new cell therapy called CART19 for teens and young adults (ages 12-29) with severe lupus that hasn't responded to other treatments. The therapy uses the patient's own immune cells to target and reduce lupus activity. The goal is to control the disease and reduc…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated May 26, 2026 05:29 UTC
-
Engineered immune cells take on lupus in first human trial
Disease control Recruiting nowThis early-phase trial tests a new treatment called MC-1-50 for adults with severe lupus that hasn't improved with standard therapies. The treatment uses a patient's own immune cells, modified to target and destroy faulty immune cells driving the disease. The main goals are to ch…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated May 26, 2026 05:27 UTC
-
Lupus patients may benefit from common vitamin
Disease control Recruiting nowThis study tests whether nicotinamide riboside, a form of vitamin B3, can reduce inflammation and improve immune function in women with mild-to-moderate lupus. About 78 women will receive either the supplement or a placebo for 12 weeks. Researchers will measure changes in immune …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated May 26, 2026 04:37 UTC
-
Lupus drug may shield fertility – new study investigates
Disease control Recruiting nowThis study looks at whether a drug called GnRHa can help preserve ovarian function in women under 40 with lupus who are treated with cyclophosphamide, a chemotherapy that can cause infertility. Researchers will survey 100 women about their menstrual history and review medical rec…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
Experimental cell therapy targets tough autoimmune conditions
Disease control Recruiting nowThis early-stage study tests a new cell therapy called YTS109 in 18 adults with autoimmune diseases like lupus and Sjogren's syndrome that have not responded to standard treatments. Participants receive a single infusion of these immune cells to see if it is safe and can help con…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New biologic combo shows promise for lupus kidney patients
Disease control Recruiting nowThis study tests whether newer biologic drugs (belimumab or telitacicept) can control active lupus kidney disease better than the standard treatment. About 50 adults with biopsy-confirmed lupus nephritis will receive either a biologic plus steroids, standard therapy (mycophenolat…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE2 • Sponsor: Nanjing University School of Medicine • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
Engineered immune cells take on lupus in first human safety trial
Disease control Recruiting nowThis early-phase study tests a new type of cell therapy (called universal CD19/20 CAR-T) in 12 adults with moderate to severe lupus that hasn't responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will also watch for signs that…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated May 22, 2026 13:55 UTC
-
Engineered immune cells take on lupus in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment called CHT101 for people with lupus that has not responded to standard therapies. CHT101 uses specially engineered immune cells (CAR-T cells) to target and attack faulty immune cells driving the disease. The study will enroll 15 partic…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New hope for lupus skin flares? phase 3 trial launches
Disease control Recruiting nowThis study tests an experimental drug called enpatoran for people with lupus that causes active skin rashes or sores. About 202 adults with lupus skin disease will receive either enpatoran or a placebo for 24 weeks, while continuing their usual treatments. The goal is to see if e…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
Experimental immune reset: could FT819 tame lupus and other autoimmune diseases?
Disease control Recruiting nowThis early-stage study tests a new cell therapy called FT819 in people with moderate-to-severe autoimmune diseases like lupus, vasculitis, myositis, and scleroderma. The goal is to see if it is safe and can reduce disease activity by targeting faulty B-cells. About 244 participan…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Cord blood cells could tame lupus – first human trial begins
Disease control Recruiting nowThis early-stage study tests a single injection of cells from donated umbilical cords in 10 adults with active lupus. The goal is to see if the treatment is safe and can improve kidney function and reduce disease activity when added to standard care. Participants will have regula…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: LiveKidney.Bio • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Engineered immune cells take on lupus in first human test
Disease control Recruiting nowThis early study tests a new treatment called universal CD19/20 CAR-T cells for people with moderate to severe lupus that hasn't responded to standard therapies. The treatment uses specially engineered immune cells to target and potentially reset the faulty immune system. The mai…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
New lupus drug enters human testing
Disease control Recruiting nowThis study tests a new medicine, DB-2304, for safety and how it works in the body. It includes healthy volunteers and people with lupus (SLE or CLE). The goal is to see if the drug is safe and to find the right dose for future studies. About 148 people will take part.
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1, PHASE2 • Sponsor: DualityBio Inc. • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
New lupus shot shows promise in Mid-Stage trial
Disease control Recruiting nowThis study tests a new medicine called SG301, given as an injection under the skin, for people with systemic lupus erythematosus (SLE). The goal is to see if it can reduce lupus disease activity better than a placebo. About 120 adults with active lupus who haven't responded well …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE2 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
Engineered immune cells take on tough lupus cases
Disease control Recruiting nowThis early-stage study tests a new treatment called QT-019B for people with refractory systemic lupus erythematosus (SLE), a severe form of lupus that hasn't responded to standard therapies. The treatment uses specially engineered immune cells (CAR-T cells) from a healthy donor t…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Hangzhou Qihan Biotech Co., Ltd. • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
New 'T cell Engager' drug tested for tough autoimmune cases
Disease control Recruiting nowThis early-phase study tests the safety of a new drug called CC312 in up to 18 adults with autoimmune diseases like lupus, arthritis, or scleroderma that haven't responded to standard treatments. CC312 works by directing the body's immune T cells to attack faulty B cells, similar…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
Lupus patients get continued access to promising drug in new study
Disease control Recruiting nowThis study provides ongoing treatment with deucravacitinib for people with lupus (SLE or DLE/SCLE) who finished a previous study. It aims to keep managing the disease long-term. Only 35 participants who are likely to benefit and meet eligibility criteria will be enrolled.
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE4 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated May 18, 2026 12:10 UTC
-
Steroid-Free hope: new lupus kidney treatment trial launches
Disease control Recruiting nowThis study tests whether a drug called obinutuzumab, combined with mycophenolate mofetil (MMF), can control lupus-related kidney disease as well as the standard treatment of oral steroids plus MMF, but without the side effects of long-term steroid use. About 196 people with activ…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated May 18, 2026 11:59 UTC
-
New drug VIS171 tested for lupus, hair loss, and kidney disease
Disease control Recruiting nowThis early-stage trial tests a new drug called VIS171 in 30 people with autoimmune diseases like lupus, alopecia areata, or a kidney condition. The main goal is to check if the drug is safe and tolerable when given as a shot under the skin. Participants will be followed for up to…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New cell therapy takes on lupus and muscle disease in early trial
Disease control Recruiting nowThis early-stage study tests a new treatment called LUCAR-G79D for adults with lupus or inflammatory myopathies that have not responded to standard therapies. The treatment uses a patient's own immune cells, modified to target and attack disease-causing cells. The main goals are …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: PHASE1 • Sponsor: Nanjing Legend Biotech Co. • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
Engineered immune cells aim to tame childhood autoimmune diseases
Disease control Recruiting nowThis study tests a new treatment using specially engineered immune cells (CAR-NK cells) in children aged 5 and older with severe rheumatic diseases like lupus that have not responded to standard therapies. The cells are designed to target and destroy faulty immune cells that caus…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
Heart scans could spot hidden danger in kids with lupus
Knowledge-focused Recruiting nowThis study looks for early signs of heart trouble in children with lupus using safe, non-invasive ultrasound scans. Researchers will measure heart size, pumping strength, and valve function in 60 participants. The goal is to find better ways to detect heart problems early, not to…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Knowledge-focused
Last updated May 26, 2026 05:29 UTC
-
Lupus patients who failed multiple drugs get closer look at what works
Knowledge-focused Recruiting nowThis study is for people with active lupus (including lupus kidney disease) who haven't gotten better with steroids and at least two immunosuppressants. Researchers will watch how well current standard treatments work over time, focusing on remission rates and safety. About 223 p…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated May 26, 2026 05:27 UTC
-
Massive lupus study aims to unlock secrets of the disease
Knowledge-focused Recruiting nowThis study is creating a large collection of health information and blood samples from 3,500 people with lupus. Researchers will use this resource to study the causes of lupus, how it affects different people, and why some treatments work better than others. The goal is to speed …
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: Lupus Research Alliance • Aim: Knowledge-focused
Last updated May 22, 2026 14:04 UTC
-
10,000 lupus patients needed for landmark online study
Knowledge-focused Recruiting nowThis study is a fully online registry for adults and children with lupus. It aims to collect information about diagnosis, treatment, and quality of life through surveys every six months. No travel is required—everything is done from home. The goal is to better understand lupus an…
Matched conditions: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Sponsor: Lupus Foundation of America • Aim: Knowledge-focused
Last updated May 14, 2026 12:02 UTC